Evidence map›Paper›PMID 41280562›Full record

ArticleAmerican journal of nuclear medicine and molecular imaging2025

Molecular tumor volume on PSMA PET/CT is an independent imaging biomarker associated with progression-free survival in patients with oligorecurrent prostate cancer.

Monica Cheng, Umar Mahmood, Nathaniel D Mercaldo, Shadi A Esfahani, Thomas Ng, Xin Gao, Jason A Efstathiou, Pedram Heidari

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Monica ChengDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School Boston, MA, USA.
Umar MahmoodDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School Boston, MA, USA.
Nathaniel D MercaldoDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School Boston, MA, USA.
Shadi A EsfahaniDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School Boston, MA, USA.
Thomas NgDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School Boston, MA, USA.
Xin GaoDepartment of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School Boston, MA, USA.
Jason A EfstathiouDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School Boston, MA, USA.
Pedram HeidariDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School Boston, MA, USA.

Funding

Molecular Imaging of Fibrosis for Improved Treatment Planning of Pancreatic Ductal AdenocarcinomaK08CA259626 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Shadi Abdar Esfahani · 2022 to 2026
$1.3M
NCI NIH HHS K08 CA259626
6 · The paper itself

Abstract

The purpose of this study is to evaluate the PSMA PET imaging parameters in association with outcomes among patients with oligorecurrent prostate cancer. This retrospective single-center study included 101 patients (median age 71; interquartile range 65-75) with biochemically recurrent prostate cancer who underwent PSMA PET between May 2021 and May 2022, revealing 5 or fewer sites of metastases (oligometastatic disease). Multiple variables including maximum standardized uptake value (SUV

Indexed as

molecular imagingPET imagingProstateprostate adenocarcinomaPSMAradiotheranosticssurvival

Identifiers

PMID41280562
PMCPMC12629906

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.